# Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

> **NCT02230176** · PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 84 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** 177Lu-DOTA0-Tyr3-Octreotate

## Key facts

- **NCT ID:** NCT02230176
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2024-04
- **Final completion:** 2024-04
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230176, "Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02230176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*